Title
Category
Credits
Event date
Cost
Cognitive Impairment in Huntington Disease
  • Movement Disorders
  • Neurology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease.
Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia.
Tweetorial: Analyzing Two Schizophrenia Case Reports
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts discuss appropriate treatment sequencing for patients with schizophrenia, including early use of LAIs and switching from an oral antipsychotic.
A Tailored Approach to Diagnosis and Early Treatment in Patients with Duchenne Muscular Dystrophy: A Real-World View of Quality of Life
  • Delivery of Care
  • Muscular Dystrophy
  • Neurology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.
Best Practices for Management of Mental Health in Women: Focusing on Mood Disorders Throughout the Lifespan
  • Patient/Physician Communication
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Diagnosis and tailored treatment of menstrual cycle- and menopausal-related mood disorders are key factors in helping women live the lives they want to live.
Untangling the Complexity of Alzheimer Disease With Effective Diagnostic Tools and Novel Treatment Options
  • Alzheimer Disease
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation
$0.00
New biomarker technology and advancements in treatment options can lead to earlier diagnosis of AD and initiation of appropriate disease modifying therapies.
Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
What is the future of schizophrenia treatment? An in-depth exploration of novel, non-dopaminergic therapies transforming the standard of care for patients with schizophrenia’s positive and negative symptoms.
Staying Up to Date with Evolving Postpartum Depression Pathophysiology and Treatment Research
  • Depression
  • Mood Disorders
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Early diagnosis of PPD is critical for mother-infant outcomes, and new hypotheses in its pathophysiology has led to novel and emerging therapies that can improve these outcomes.
Optimizing Mental Health for Women: Recognizing and Treating Mood Disorders Throughout the Lifespan
  • Mood Disorders
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Program IntroductionMood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.Learning ObjectivesAfter completing this educational activity, you should be able to:

Pages